Synopsis
Synopsis
0
VMF
DRUG PRODUCT COMPOSITIONS0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. 2-butyl-4-chloro-1-((2'-(1h-etrazol-5-yl) (1,1'-biphenyl)-4-yl)methyl)-1h-imidazole-5-methanol
2. Cozaar
3. Dup 753
4. Dup-753
5. Dup753
6. Losartan
7. Losartan Monopotassium Salt
8. Mk 954
9. Mk-954
10. Mk954
11. Monopotassium Salt, Losartan
12. Potassium, Losartan
13. Salt, Losartan Monopotassium
1. 124750-99-8
2. Cozaar
3. Losartan Potassium Salt
4. Lorzaar
5. Losacar
6. Losaprex
7. Hyzaar
8. Dup 753
9. Nu-lotan
10. Mk 954
11. Lortaan
12. Losata
13. Tancin
14. Mk-0954
15. Losartanpotassium
16. Losartan Potassium (dup 753)
17. Mk0954
18. L-158086
19. Losartan Monopotassium Salt
20. 3st302b24a
21. Aradois
22. Zaart
23. Dup-753
24. Presartan-50
25. E-3340
26. 2-butyl-4-chloro-1-(p-(o-1h-tetrazol-5-ylphenyl)benzyl)imidazole-5-methanol, Monopotassium Salt
27. 124750-99-8 (ka+)
28. Potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,3-triaza-4-azanidacyclopenta-2,5-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol
29. Lifezar
30. Lorzaan
31. Losacor
32. Tenopres
33. Lotim
34. Niten
35. Ocsaar
36. Du Pont-753
37. Neo Lotan
38. 1h-imidazole-5-methanol, 2-butyl-4-chloro-1-((2'-(1h-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl)-, Monopotassium Salt
39. 2-butyl-4-chloro-1-[[2'-(1h-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1h-imidazole-5-methanol, Monopotassium Salt
40. Mfcd09850721
41. Mk-954
42. Du Pont 753
43. Losartan Potassium [usan]
44. Covance
45. Unii-3st302b24a
46. Losartan Potassium [usan:usp]
47. Potassium 5-(4'-((2-butyl-4-chloro-5-(hydroxymethyl)-1h-imidazol-1-yl)methyl)biphenyl-2-yl)tetrazol-1-ide
48. Cozaar (tn)
49. Dup-753 Potassium
50. Mk 0954
51. Losartan Potassium,(s)
52. Schembl42079
53. Mls001401407
54. Ex-89
55. Dtxsid3044209
56. Losartan Potassium [jan]
57. Losartan Potassium (jp17/usp)
58. Losartan Potassium [hsdb]
59. Hms2051m12
60. Hms2090o22
61. Hms2235f20
62. Hms3369f08
63. Hms3393m12
64. Losartan Potassium [vandf]
65. Losartan Potassium [mart.]
66. Act02618
67. Bcp05332
68. Bcp29397
69. Losartan Potassium [usp-rs]
70. Losartan Potassium [who-dd]
71. Akos015955543
72. Akos025310168
73. Ac-1072
74. Ccg-100869
75. Losartan Potassium, Analytical Standard
76. Nc00119
77. 2-butyl-4-chloro-1-(2'-(tetrazol-5-yl)biphenyl-4-ylmethyl)-1h-imidazole-5-methanol Potassium
78. Losartan Monopotassium Salt [mi]
79. Losartan Potassium [orange Book]
80. Losartan Potassium [ep Monograph]
81. 2-butyl-4-chloro-1-[[2'-(1h-tetrazol-5-yl)-1,1'-biphenyl-4-yl]methyl]imidazole-5-methanol Potassium Salt
82. Bl164642
83. Epo
84. Hyzaar Component Losartan Potassium
85. Losartan Potassium [usp Monograph]
86. Smr000469593
87. Ft-0625705
88. L-185
89. L0232
90. Losartan Potassium Component Of Hyzaar
91. D00357
92. Ab01275507-01
93. 750l998
94. A805291
95. Sr-05000001514
96. Sr-05000001514-1
97. Q27257991
98. Losartan Potassium, European Pharmacopoeia (ep) Reference Standard
99. Losartan Potassium Is Known As A Potent, Synthetic At1 Receptor Antagonist.
100. Losartan Potassium, United States Pharmacopeia (usp) Reference Standard
101. Losartan Potassium, Pharmaceutical Secondary Standard; Certified Reference Material
102. [2-butyl-5-chloro-3-[[4-[2-(1,2,3-triaza-4-azanidacyclopenta-2,5-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol; Potassium;losartan Potassium
103. 1h-imidazole-5-methanol, 2-butyl-4-chloro-1-((2-(1h-tetrazol-5-yl)(1,1-biphenyl)-4-yl)methyl)-, Monopotassium Salt
104. Potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,3-triaza-4-azanidacyclopenta-2,5-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol.
| Molecular Weight | 461.0 g/mol |
|---|---|
| Molecular Formula | C22H22ClKN6O |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 6 |
| Rotatable Bond Count | 8 |
| Exact Mass | 460.1180685 g/mol |
| Monoisotopic Mass | 460.1180685 g/mol |
| Topological Polar Surface Area | 77.7 Ų |
| Heavy Atom Count | 31 |
| Formal Charge | 0 |
| Complexity | 526 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 2 |
| 1 of 4 | |
|---|---|
| Drug Name | Cozaar |
| PubMed Health | Losartan (By mouth) |
| Drug Classes | Cardiovascular Agent, Renal Protective Agent |
| Drug Label | COZAAR1(losartan potassium) is an angiotensin II receptor (type AT1) antagonist. Losartan potassium, a non-peptide molecule, is chemically described as 2-butyl-4-chloro-1-[p-(o-1H-tetrazol-5-ylphenyl)benzyl]imidazole-5-methanol monopotassium salt.Its... |
| Active Ingredient | Losartan potassium |
| Dosage Form | Tablet |
| Route | Oral |
| Strength | 100mg; 25mg; 50mg |
| Market Status | Prescription |
| Company | Merck Sharp Dohme |
| 2 of 4 | |
|---|---|
| Drug Name | Losartan potassium |
| Drug Label | Losartan potassium tablets USP are an angiotensin II receptor (type AT1) antagonist. Losartan potassium, USP a non-peptide molecule, is chemically described as 2-butyl-4-chloro-1-[p-(o-1H-tetrazol-5-ylphenyl)benzyl]imidazole-5-methanol monopotassium... |
| Active Ingredient | Losartan potassium |
| Dosage Form | Tablet |
| Route | Oral |
| Strength | 25mg; 100mg; 50mg |
| Market Status | Prescription |
| Company | Upsher Smith; Teva; Apotex; Alembic Pharms; Aurobindo Pharma; Torrent Pharms; Lupin; Sandoz; Prinston; Roxane; Watson Labs; Macleods Pharms; Ipca Labs; Vivimed Labs; Micro Labs Ltd India; Cadista Pharms; Zydus Pharms Usa; Mylan |
| 3 of 4 | |
|---|---|
| Drug Name | Cozaar |
| PubMed Health | Losartan (By mouth) |
| Drug Classes | Cardiovascular Agent, Renal Protective Agent |
| Drug Label | COZAAR1(losartan potassium) is an angiotensin II receptor (type AT1) antagonist. Losartan potassium, a non-peptide molecule, is chemically described as 2-butyl-4-chloro-1-[p-(o-1H-tetrazol-5-ylphenyl)benzyl]imidazole-5-methanol monopotassium salt.Its... |
| Active Ingredient | Losartan potassium |
| Dosage Form | Tablet |
| Route | Oral |
| Strength | 100mg; 25mg; 50mg |
| Market Status | Prescription |
| Company | Merck Sharp Dohme |
| 4 of 4 | |
|---|---|
| Drug Name | Losartan potassium |
| Drug Label | Losartan potassium tablets USP are an angiotensin II receptor (type AT1) antagonist. Losartan potassium, USP a non-peptide molecule, is chemically described as 2-butyl-4-chloro-1-[p-(o-1H-tetrazol-5-ylphenyl)benzyl]imidazole-5-methanol monopotassium... |
| Active Ingredient | Losartan potassium |
| Dosage Form | Tablet |
| Route | Oral |
| Strength | 25mg; 100mg; 50mg |
| Market Status | Prescription |
| Company | Upsher Smith; Teva; Apotex; Alembic Pharms; Aurobindo Pharma; Torrent Pharms; Lupin; Sandoz; Prinston; Roxane; Watson Labs; Macleods Pharms; Ipca Labs; Vivimed Labs; Micro Labs Ltd India; Cadista Pharms; Zydus Pharms Usa; Mylan |
Indicated in adult and paediatric patients for the: - treatment of anemia due to Chronic Kidney Disease (CKD) in patients on dialysis and not on dialysis. - treatment of anemia due to zidovudine in patients with HIV-infection. - treatment of anemia due to the effects of concomitant myelosuppressive chemotherapy, and upon initiation, there is a minimum of two additional months of planned chemotherapy. - reduction of allogeneic RBC transfusions in patients undergoing elective, noncardiac, nonvascular surgery.
FDA Label
Proteinuria, Treatment of heart failure, Treatment of hypertension
Erythropoietin and epoetin alfa are involved in the regulation of erythrocyte differentiation and the maintenance of a physiological level of circulating erythrocyte mass. It is reported to increase the reticulocyte count within 10 days of initiation, followed by increases in the RBC count, hemoglobin, and hematocrit, usually within 2 to 6 weeks. Depending on the dose administered, the rate of hemoglobin increase may vary. In patients receiving hemodialysis, a greater biologic response is not observed at doses exceeding 300 Units/kg 3 times weekly. Epoetin alfa serves to restore erythropoietin deficiency in pathological and other clinical conditions where normal production of erythropoietin is impaired or compromised. In anemic patients with chronic renal failure (CRF), administration with epoetin alfa stimulated erythropoiesis by increasing the reticulocyte count within 10 days, followed by increases in the red cell count, hemoglobin, and hematocrit, usually within 2 to 6 weeks. Epoetin alfa was shown to be effective in increasing hematocrit in zidovudine-treated HIV-infected patients and anemic cancer patients undergoing chemotherapy.
Angiotensin II Type 1 Receptor Blockers
Agents that antagonize ANGIOTENSIN II TYPE 1 RECEPTOR. Included are ANGIOTENSIN II analogs such as SARALASIN and biphenylimidazoles such as LOSARTAN. Some are used as ANTIHYPERTENSIVE AGENTS. (See all compounds classified as Angiotensin II Type 1 Receptor Blockers.)
Anti-Arrhythmia Agents
Agents used for the treatment or prevention of cardiac arrhythmias. They may affect the polarization-repolarization phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibers. Anti-arrhythmia agents are often classed into four main groups according to their mechanism of action: sodium channel blockade, beta-adrenergic blockade, repolarization prolongation, or calcium channel blockade. (See all compounds classified as Anti-Arrhythmia Agents.)
Antihypertensive Agents
Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS. (See all compounds classified as Antihypertensive Agents.)
B - Blood and blood forming organs
B03 - Antianemic preparations
B03X - Other antianemic preparations
B03XA - Other antianemic preparations
B03XA01 - Erythropoietin
Absorption
The time to reach peak concentration is slower via the subcutaneous route than the intravenous route which ranges from 20 to 25 hours, and the peak is always well below the peak achieved using the intravenous route (510% of those seen with IV administration). The bioavailability of subcutaneous injectable erythropoietin is much lower than that of the intravenously administered product and is approximately 20-40%. **Adult and paediatric patients with CRF:** Following subcutaneous administration, the peak plasma levels are achieved within 5 to 24 hours. **Cancer patients receiving cyclic chemotherapy:** The average time to reach peak plasma concentration was approximately 13.3 12.4 hours after 150 Units/kg three times per week (TIW) subcutaneous (SC) dosing. The Cmax is expected be 3- to 7- fold higher and the Tmax is expected to be 2- to 3-fold longer in patients receiving a 40,000 Units SC weekly dosing regimen.
Route of Elimination
Erythropoietin and epoetin alfa are cleared via uptake and degradation via the EPO-R-expressing cells, and may also involve other cellular pathways in the interstitium, probably via cells in the reticuloendothelial scavenging pathway or lymphatic system. Only a small amount of unchanged epoetin alfa is found in the urine.
Volume of Distribution
In healthy volunteers, the volume of distribution of intravenous epoetin alfa was generally similar to the plasma volume (range of 4063.80 mL/kg), indicating limited extravascular distribution.
Clearance
**Healthy volunteers: *
In male volunteers receiving intravenous epoetin alfa, the total body clearance was approximately 8.12 1.00 mL/h/kg. **Cancer patients receiving cyclic chemotherapy:*
The average clearance was approximately 20.2 15.9 mL/h/kg after 150 Units/kg three times per week (TIW) subcutaneous (SC) dosing. The patients receiving a 40,000 Units SC weekly dosing regimen display a lower clearance (9.2 4.7 mL/h/kg).
Binding of erythropoietin and epoetin alfa to EPO-R leads to cellular internalization, which involves the degradation of the ligand. Erythropoietin and epoetin alfa may also be degraded by the reticuloendothelial scavenging pathway or lymphatic system.
**Healthy volunteers:*
The half life is approximately 4 hours in healthy volunteers receiving an intravenous injection. A half-life of approximately 6 hours has been reported in children. **Adult and paediatric patients with CRF:*
The elimination half life following intravenous administration ranges from 4 to 13 hours, which is about 20% longer in CRF patients than that in healthy subjects. The half life is reported to be similar between adult patients receiving or not receiving dialysis. **Cancer patients receiving cyclic chemotherapy:*
Following subcutaneous administration, the average half life is 40 hours with range of 16 to 67 hours.
Erythropoietin or exogenous epoetin alfa binds to the erythropoietin receptor (EPO-R) and activates intracellular signal transduction pathways. The affinity (Kd) of EPO for its receptor on human cells is 100 to 200 pM. Upon binding to EPO-R on the surface of erythroid progenitor cells, a conformational change is induced which brings EPO-R-associated Janus family tyrosine protein kinase 2 (JAK2) molecules into close proximity. JAK2 molecules are subsequently activated via phosphorylation, then phosphorylate tyrosine residues in the cytoplasmic domain of the EPO-R that serve as docking sites for Src homology 2-domain-containing intracellular signaling proteins. The signalling proteins include STAT5 that once phosphorylated by JAK2, dissociates from the EPO-R, dimerizes, and translocates to the nucleus where they serve as transcription factors to activate target genes involved in cell division or differentiation, including the apoptosis inhibitor Bcl-x. The inhibition of apoptosis by the EPO-activated JAK2/STAT5/Bcl-x pathway is critical in erythroid differentiation. Via JAK2-mediated tyrosine phosphorylation, erythropoietin and epoetin alfa also activates other intracellular proteins involved in erythroid cell proliferation and survival, such as Shc , phosphatidylinositol 3-kinase (PI3K), and phospholipase C-1.
API SUPPLIERS
Nuray is an expert in the synthesis of Niche novel APIs, the first to launch Generics, NCEs, Advanced Intermediates // USFDA certified.
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 20358
Submission : 2007-03-20
Status : Active
Type : II
Registration Number : 222MF10263
Registrant's Address : 8-2-337, Road No. 3, Banjara Hills, Hyderabad 500 034, TELANGANA, INDIA
Initial Date of Registration : 2010-11-29
Latest Date of Registration :
Date of Issue : 2025-06-20
Valid Till : 2028-07-07
Written Confirmation Number : WC-0039
Address of the Firm :
NDC Package Code : 71796-042
Start Marketing Date : 2021-12-03
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Registrant Name : Sangjin Trading Co., Ltd.
Registration Date : 2022-06-14
Registration Number : 20220614-122-G-166-39
Manufacturer Name : Dr. Reddy's Laboratories Ltd.
Manufacturer Address : CTO-Unit-V ,Peddadevulapally Village,Tripuraram Mandal, Nalgonda District, Telangana - 508207,INDIA
| Available Reg Filing : ASMF |
Gonane has API manufacturing expertise in new-age Corticosteroids, Hormones and other pharma raw materials.
IOL Chemicals is an innovation-driven bulk drug, Intermediate and Specialty Chemicals company.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 37106
Submission : 2022-09-23
Status : Active
Type : II
Certificate Number : CEP 2022-380 - Rev 00
Issue Date : 2024-02-05
Type : Chemical
Substance Number : 2232
Status : Valid
Date of Issue : 2025-02-27
Valid Till : 2028-03-17
Written Confirmation Number : WC-0004
Address of the Firm :
NDC Package Code : 49716-333
Start Marketing Date : 2023-10-15
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Jai Radhe Sales is your partner for all your sourcing needs.
HRV Pharma - Market Expansion Leader in Pharmaceuticals.
Octavius Pharma has been empowering lives since 1980 by providing quality products like DC granules, APIs and FDFs.
Tagoor's product development expertise, backed by our comprehensive understanding of the processes, helps us offer high-quality APIs.
Date of Issue : 2024-08-16
Valid Till : 2027-02-26
Written Confirmation Number : WC-0494
Address of the Firm :
Tenatra connects Indian manufacturers with global buyers through active partners in Germany, Switzerland, Belgium, Spain & Turkey.
Zeon Pharma is a manufacturer and supplier of APIs & Intermediates.
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
USDMF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]CEP/COS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] EU WC
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]NDC API
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Listed Suppliers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]API Reference Price
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us 
Drugs in Development
Details:
Generic of Losartan potassium and hydrochlorothiazide tablets are been approved by FDA, indicated for hypertension to lower blood pressure and to reduce the risk of stroke.
Lead Product(s): Losartan Potassium,Hydrochlorothiazide
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Cozaar-Generic
Study Phase: Approved FDFProduct Type: Hormone
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 30, 2023
Lead Product(s) : Losartan Potassium,Hydrochlorothiazide
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Granules India Limited Received ANDA Approval for Losartan and Hydrochlorothiazide Tablets
Details : Generic of Losartan potassium and hydrochlorothiazide tablets are been approved by FDA, indicated for hypertension to lower blood pressure and to reduce the risk of stroke.
Product Name : Cozaar-Generic
Product Type : Hormone
Upfront Cash : Inapplicable
September 30, 2023
Details:
Losartan potassium prevention of angiotensin II binding causes vascular smooth muscle relaxation, lowering blood pressure. Angiotensin II would otherwise bind to the AT1 receptor and induce vasoconstriction, raising blood pressure.
Lead Product(s): Losartan Potassium,Inapplicable
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Cozaar-Generic
Study Phase: Approved FDFProduct Type: Hormone
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 27, 2023
Lead Product(s) : Losartan Potassium,Inapplicable
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Granules Gets USFDA Nod to Market Generic Medication to Treat High Blood Pressure
Details : Losartan potassium prevention of angiotensin II binding causes vascular smooth muscle relaxation, lowering blood pressure. Angiotensin II would otherwise bind to the AT1 receptor and induce vasoconstriction, raising blood pressure.
Product Name : Cozaar-Generic
Product Type : Hormone
Upfront Cash : Inapplicable
February 27, 2023
Details:
The collaboration aims to advance the clinical development of Losartan Potassium, a hormone targeting the Type-1 angiotensin II receptor.
Lead Product(s): Losartan Potassium,Inapplicable
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Arbli
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Blink Rx
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration December 10, 2025
Lead Product(s) : Losartan Potassium,Inapplicable
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Blink Rx
Deal Size : Undisclosed
Deal Type : Collaboration
Scienture, BlinkRx Collaborate to Expand Patient Access to Arbli™, First FDA-Approved Losartan O...
Details : The collaboration aims to advance the clinical development of Losartan Potassium, a hormone targeting the Type-1 angiotensin II receptor.
Product Name : Arbli
Product Type : Miscellaneous
Upfront Cash : Undisclosed
December 10, 2025
Details:
ZYN002 is a Controlled Substance drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Lead Product(s): Cannabidiol,Midazolam,Omeprazole,Losartan Potassium,Dextromethorphan,Caffeine,Repaglinide,Bupropion Hydrochloride
Therapeutic Area: Undisclosed Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Controlled Substance
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 16, 2025
Lead Product(s) : Cannabidiol, Midazolam, Omeprazole, Losartan Potassium, Dextromethorphan
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Drug Interaction Study of ZYN002 Transdermal Gel and Probe Substrates
Details : ZYN002 is a Controlled Substance drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
April 16, 2025
Details:
Arbli (losartan potassium) is an angiotensin II receptor blocker indicated for hypertension, to lower blood pressure in adults and children greater than 6 years old.
Lead Product(s): Losartan Potassium,Inapplicable
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Arbli
Study Phase: Approved FDFProduct Type: Hormone
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 18, 2025
Lead Product(s) : Losartan Potassium,Inapplicable
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
SCIENTURE Gains FDA Nod for SCN-102, Branded as Arbli (Losartan Suspension)
Details : Arbli (losartan potassium) is an angiotensin II receptor blocker indicated for hypertension, to lower blood pressure in adults and children greater than 6 years old.
Product Name : Arbli
Product Type : Hormone
Upfront Cash : Inapplicable
March 18, 2025
Details:
9-ING-41 (elraglusib), a novel GSK-3 inhibitor, targets molecular pathways in cancer that are involved in promoting tumor growth. It is being investigated for metastatic pancreatic cancer.
Lead Product(s): Elraglusib,Gemcitabine,Losartan Potassium
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 25, 2025
Lead Product(s) : Elraglusib,Gemcitabine,Losartan Potassium
Therapeutic Area : Oncology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Actuate Completes Enrollment in Phase 2 Elraglusib Trial for Pancreatic Cancer
Details : 9-ING-41 (elraglusib), a novel GSK-3 inhibitor, targets molecular pathways in cancer that are involved in promoting tumor growth. It is being investigated for metastatic pancreatic cancer.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 25, 2025
Details:
Kwality Pharmaceuticals gains RCGM approval for preclinical toxicity studies of recombinant Erythropoietin, advancing its biologics portfolio and targeting CKD-related anemia treatment.
Lead Product(s): Losartan Potassium,Inapplicable
Therapeutic Area: Hematology Brand Name: Undisclosed
Study Phase: PreclinicalProduct Type: Hormone
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 02, 2025
Lead Product(s) : Losartan Potassium,Inapplicable
Therapeutic Area : Hematology
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Kwality Pharma Gains on Securing RCGM Approval for Erythropoietin
Details : Kwality Pharmaceuticals gains RCGM approval for preclinical toxicity studies of recombinant Erythropoietin, advancing its biologics portfolio and targeting CKD-related anemia treatment.
Product Name : Undisclosed
Product Type : Hormone
Upfront Cash : Inapplicable
January 02, 2025
Details:
Losartan Potassium is a Hormone drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Lead Product(s): Losartan Potassium,Inapplicable
Therapeutic Area: Undisclosed Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Hormone
Sponsor: Oxford Health Biomedical Research Centre (OH BRC) support scheme
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 15, 2024
Lead Product(s) : Losartan Potassium,Inapplicable
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Oxford Health Biomedical Research Centre (OH BRC) support scheme
Deal Size : Inapplicable
Deal Type : Inapplicable
Losartan and Emotional Processing in Young People
Details : Losartan Potassium is a Hormone drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Hormone
Upfront Cash : Inapplicable
October 15, 2024
Details:
Losartan Potassium is a Hormone drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Lead Product(s): Losartan Potassium,Inapplicable
Therapeutic Area: Undisclosed Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Hormone
Sponsor: Oxford Health Biomedical Research Centre (OH BRC) support scheme
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 04, 2024
Lead Product(s) : Losartan Potassium,Inapplicable
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Oxford Health Biomedical Research Centre (OH BRC) support scheme
Deal Size : Inapplicable
Deal Type : Inapplicable
Losartan and Emotional Learning
Details : Losartan Potassium is a Hormone drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Hormone
Upfront Cash : Inapplicable
October 04, 2024
Details:
Losartan Potassium is a Hormone drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Lead Product(s): Losartan Potassium,Inapplicable
Therapeutic Area: Undisclosed Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Hormone
Sponsor: Oxford Health Biomedical Research Centre (OH BRC) support scheme
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 03, 2024
Lead Product(s) : Losartan Potassium,Inapplicable
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Oxford Health Biomedical Research Centre (OH BRC) support scheme
Deal Size : Inapplicable
Deal Type : Inapplicable
Losartan and Social Processing
Details : Losartan Potassium is a Hormone drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Hormone
Upfront Cash : Inapplicable
October 03, 2024
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]INTERMEDIATE SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDA Orange Book
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Europe
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Canada
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Australia
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]DRUG PRODUCT COMPOSITIONS
DOSAGE - TABLET;ORAL - 100MG
USFDA APPLICATION NUMBER - 20386
DOSAGE - TABLET;ORAL - 25MG
USFDA APPLICATION NUMBER - 20386
DOSAGE - TABLET;ORAL - 50MG
USFDA APPLICATION NUMBER - 20386
DOSAGE - TABLET;ORAL - 12.5MG;100MG
USFDA APPLICATION NUMBER - 20387
DOSAGE - TABLET;ORAL - 12.5MG;50MG
USFDA APPLICATION NUMBER - 20387
DOSAGE - TABLET;ORAL - 25MG;100MG
USFDA APPLICATION NUMBER - 20387
Related Excipient Companies
Rochem International Inc
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]SPI Pharma
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Boai NKY Pharmaceuticals Ltd
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Gangwal Healthcare
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Nanjing Well Pharmaceutical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Pfanstiehl
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Kirsch Pharma
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Dr. Paul Lohmann GmbH & Co. KGaA
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]ACG Worldwide
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Actylis
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Aeon Procare
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Anhui Sunhere Pharmaceutical Excipients Co.,Ltd
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Ashland
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Avesta Pharma
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Clariant
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Corel Pharma Chem
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]DFE Pharma
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Esteem Industries
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Finar
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Gangwal Chemicals
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Ideal Cures
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Ingredion Pharma Solutions
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Kerry
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Keval Exports
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Kima Chemical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Lonza Capsugel
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Microlex e.U
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Neelkanth MineChem
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Nitika Pharmaceutical Specialities
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Nomisma Healthcare
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Novo Excipients
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Pharmatrans-Sanaq
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Pluviaendo
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Prachin Chemical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Qianhao Chemical (Hebei) Co., Ltd
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Qualicaps
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Roquette
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Seppic
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Shanghai Shenmei Pharmaceutical Technology Co., Ltd
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Shijiazhuang Huaxu Pharmaceutical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Sigachi Industries
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Silverline Chemicals
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]The Dow Chemical Company
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Valens Pharmachem
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Excipients by Applications
Fillers, Diluents & Binders
Coating Systems & Additives
Direct Compression
Disintegrants & Superdisintegrants
Granulation
Controlled & Modified Release
Thickeners and Stabilizers
Lubricants & Glidants
Chewable & Orodispersible Aids
Film Formers & Plasticizers
Topical
Taste Masking
Solubilizers
Parenteral
Co-Processed Excipients
Emulsifying Agents
Empty Capsules
API Stability Enhancers
Vegetarian Capsules
Rheology Modifiers
Surfactant & Foaming Agents
Coloring Agents
Digital Content
DATA COMPILATION #PharmaFlow
NEWS #PharmaBuzz
Global Sales Information
US Medicaid Prescriptions
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ANALYTICAL
ABOUT THIS PAGE
34
PharmaCompass offers a list of Losartan Potassium API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Losartan Potassium manufacturer or Losartan Potassium supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Losartan Potassium manufacturer or Losartan Potassium supplier.
PharmaCompass also assists you with knowing the Losartan Potassium API Price utilized in the formulation of products. Losartan Potassium API Price is not always fixed or binding as the Losartan Potassium Price is obtained through a variety of data sources. The Losartan Potassium Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Lotim manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Lotim, including repackagers and relabelers. The FDA regulates Lotim manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Lotim API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Lotim manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Lotim supplier is an individual or a company that provides Lotim active pharmaceutical ingredient (API) or Lotim finished formulations upon request. The Lotim suppliers may include Lotim API manufacturers, exporters, distributors and traders.
click here to find a list of Lotim suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Lotim DMF (Drug Master File) is a document detailing the whole manufacturing process of Lotim active pharmaceutical ingredient (API) in detail. Different forms of Lotim DMFs exist exist since differing nations have different regulations, such as Lotim USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Lotim DMF submitted to regulatory agencies in the US is known as a USDMF. Lotim USDMF includes data on Lotim's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Lotim USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Lotim suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Lotim Drug Master File in Japan (Lotim JDMF) empowers Lotim API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Lotim JDMF during the approval evaluation for pharmaceutical products. At the time of Lotim JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Lotim suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Lotim Drug Master File in Korea (Lotim KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Lotim. The MFDS reviews the Lotim KDMF as part of the drug registration process and uses the information provided in the Lotim KDMF to evaluate the safety and efficacy of the drug.
After submitting a Lotim KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Lotim API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Lotim suppliers with KDMF on PharmaCompass.
A Lotim CEP of the European Pharmacopoeia monograph is often referred to as a Lotim Certificate of Suitability (COS). The purpose of a Lotim CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Lotim EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Lotim to their clients by showing that a Lotim CEP has been issued for it. The manufacturer submits a Lotim CEP (COS) as part of the market authorization procedure, and it takes on the role of a Lotim CEP holder for the record. Additionally, the data presented in the Lotim CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Lotim DMF.
A Lotim CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Lotim CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Lotim suppliers with CEP (COS) on PharmaCompass.
A Lotim written confirmation (Lotim WC) is an official document issued by a regulatory agency to a Lotim manufacturer, verifying that the manufacturing facility of a Lotim active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Lotim APIs or Lotim finished pharmaceutical products to another nation, regulatory agencies frequently require a Lotim WC (written confirmation) as part of the regulatory process.
click here to find a list of Lotim suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Lotim as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Lotim API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Lotim as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Lotim and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Lotim NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Lotim suppliers with NDC on PharmaCompass.
Lotim Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Lotim GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Lotim GMP manufacturer or Lotim GMP API supplier for your needs.
A Lotim CoA (Certificate of Analysis) is a formal document that attests to Lotim's compliance with Lotim specifications and serves as a tool for batch-level quality control.
Lotim CoA mostly includes findings from lab analyses of a specific batch. For each Lotim CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Lotim may be tested according to a variety of international standards, such as European Pharmacopoeia (Lotim EP), Lotim JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Lotim USP).
